Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda to ally with Sage Bionetworks on drug research

Takeda to ally with Sage Bionetworks on drug research

12th November 2010

Takeda is entering into an alliance with the not-for-profit biomedical research organisation Sage Bionetworks in order to advance studies on central nervous system (CNS) disease treatments.

The organisations have signed a four-year deal that will see them collaborate on the discovery of effective therapeutic targets for CNS disease, based on clinical, genetic and molecular analysis.

Under the terms of the agreement, Takeda will provide more than $3.6 million (2.2 million pounds) in research funding, while Sage will be responsible for creating a predictive model to identify key regulatory genes and predictive biomarkers in patients.

Scientists from both companies will work together to isolate the most promising potential therapies for CNS disease, which represents an underserved area of research.

Dr Paul Chapman, general manager and head of the pharmaceutical research division of Takeda, said: "Sage Bionetworks' leading-edge technology and worldwide reach offer the potential for Takeda to understand currently unknown disease mechanisms."

Earlier this month, Takeda announced that it will be commencing a phase III study of a new prostate cancer drug, in association with its oncology subsidiary Millennium.ADNFCR-8000103-ID-800232386-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.